Wannabe Genetics Project
We do not own the music and we respect the owners and its copyrights. The full instrumental is used only for demo and project purposes. A project of a Lasall...

By: Bryce De La Cruz

Continued here:
Wannabe Genetics Project - Video

Recommendation and review posted by Bethany Smith

[Attack of the B-Team ITA] Advanced Genetics - #6
Benvenuti in questa nuova serie di Minecraft, nella Modpack Attack of the B-Team, che potete trovare nel Technic Launcher 😉 Canale di Spensie: http://www.yo...

By: MineIT

See original here:
[Attack of the B-Team ITA] Advanced Genetics - #6 - Video

Recommendation and review posted by Bethany Smith

Minecraft: Attack Of The B-Team Part 5 - Teleportation With Advanced Genetics
Facebook: https://www.facebook.com/Masculineish Twitter: https://twitter.com/Masculineish What #39;s up people of YouTube? This Minecraft series is going to be r...

By: Masculineish

Continued here:
Minecraft: Attack Of The B-Team Part 5 - Teleportation With Advanced Genetics - Video

Recommendation and review posted by Bethany Smith

Minecraft Attack of the B Team SMP E05 "Advanced Genetics Basics"
Hello from the IntricateAffect SMP Attack of the B Team Server! We doing the basics of Advanced Genetics! Interested in this Game and Mod Step 1. Get Minecra...

By: Sigcraft

See the rest here:
Minecraft Attack of the B Team SMP E05 "Advanced Genetics Basics" - Video

Recommendation and review posted by Bethany Smith

Tuto Advanced Genetics part 1
Premier tuto de ma chaine sur le mod Advanced genetics.

By: Oracle tuto et gaming

View original post here:
Tuto Advanced Genetics part 1 - Video

Recommendation and review posted by Bethany Smith

Complex Genetics

By: MajorBiology

Originally posted here:
Complex Genetics - Video

Recommendation and review posted by Bethany Smith

Let #39;s Play The Sims 3 - Perfect Genetics Challenge - Episode 6
VampireClan #VampireClan4Life.

By: vampiregirl101101101

Go here to read the rest:
Let's Play The Sims 3 - Perfect Genetics Challenge - Episode 6 - Video

Recommendation and review posted by Bethany Smith

Let #39;s Play The Sims 3 - Perfect Genetics Challenge - Episode 7
VampireClan #VampireClan4Life.

By: vampiregirl101101101

Here is the original post:
Let's Play The Sims 3 - Perfect Genetics Challenge - Episode 7 - Video

Recommendation and review posted by Bethany Smith

Sequenom announced this week that CEO Harry Hixson plans to retire from that position in June, at the time of the company's stockholder meeting. Current President and Chief Operating Officer William Welch will assume Hixson's position upon his retirement. Hixson will continue to serve as chairman of the firm's board of directors, a title he has held since 2003. Welch also will be nominated to serve on the board at the annual meeting, Sequenom said. Also, CFO Paul Maier also will retire from his job in June, but will continue to work with the company as a consultant. Current VP and Chief Accounting Officer Carolyn Beaver will replace Maier as CFO upon his retirement. She previously was corporate VP and controller of Beckman Coulter. In addition, Dirk van den Boom will be promoted to be chief scientific and strategy officer. He has been with Sequenom since 1998, and he recently was the company's executive VP of R&D and chief technology officer.

Former Life Technologies executive Paul Grossman has joined Telegraph Hill Partners as a venture partner. Grossman previously was head of global strategy and corporate development at Life Tech, and he also held the same position at Invitrogen. Before he joined Invitrogen, Grossman held a variety of leadership roles at Applied Biosystems, including as a research scientist and patent attorney, VP of intellectual property, and VP of strategy and business development.

Becton Dickinson has appointed Amit Bhalla to be VP of global strategy and development. In the role, Bhalla will work with the senior management team to develop BD's overall strategy. Bhalla joins BD from Citi, where he has been director of equity research for life science tools and medical technology since 2006. Before joining Citi, he was VP of equity research for emerging medical technology at Morgan Stanley, and a technical operations R&D associate at Johnson and Johnson.

See more here:
Genetics in Healthcare

Recommendation and review posted by Bethany Smith

Share prices of NewLink Genetics Corporation ( NLNK ) fell 16.2% after the independent review committee recommended continuation of its phase III pancreatic cancer study (IMPRESS) of HyperAcute Pancreas following the first interim data analyses. The investors had expected the committee to terminate the trial early on the back of high efficacy levels. The first interim analysis evaluated 222 patients.

NewLink Genetics expected the study to continue, bearing in mind the high statistical threshold assigned to the first interim analysis under the special protocol assessment. There were no safety issues and other concerns raised by the independent data monitoring committee.

The second interim analysis evaluating 333 patients will be initiated and if required, a final analysis will be conducted on 444 patients.

We remind investors that HyperAcute Pancreas, NewLink Genetics' lead candidate, is being studied in a phase III study, IMPRESS (Immunotherapy for Pancreatic Resectable cancer Survival Study). The study under a Special Protocol Assessment completed enrolment of 722 patients with surgically resected pancreatic cancer in the third quarter of 2013.

HyperAcute Pancreas is also being tested in another phase III study, PILLAR (Pancreatic Immunotherapy with algenpantucel-L for Locally Advanced non-Resectable), evaluating patients with locally advanced pancreatic cancer. This study is currently enrolling patients. The two phase III studies, IMPRESS and PILLAR, were started on the basis of encouraging phase II data which demonstrated improvement in both disease-free and overall survival.

The U.S. Food and Drug Administration granted this candidate fast track and orphan drug designation for the adjuvant treatment of surgically-resected pancreatic cancer. The European Commission granted orphan medicinal product designation to this candidate as well.

NewLink Genetics carries a Zacks Rank #3 (Hold). Investors looking for better-ranked stocks in the biopharma sector may consider companies like Gilead Sciences Inc. ( GILD ), Shire ( SHPG ) and Alkermes ( ALKS ). Gilead Sciences carries a Zacks Rank #2 (Buy) while Shire and Alkermes carry a Zacks Rank #1 (Strong Buy).

ALKERMES INC (ALKS): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

NEWLINK GENETIC (NLNK): Free Stock Analysis Report

View post:
NewLink Genetics' Shares Sink - Analyst Blog

Recommendation and review posted by Bethany Smith

An inspirational quadriplegic surfer - Barney Miller: A day in the life
Click http://win.gs/1hNLO5D to join the world in running for those who can #39;t! Wings for Life World Run Ambassador, Barney Miller, gives an inside look into w...

By: Red Bull

The rest is here:
An inspirational quadriplegic surfer - Barney Miller: A day in the life - Video

Recommendation and review posted by sam

A surfer #39;s optimism after tragic spinal cord injury - Brooke Thabit: A day in the life
Click http://win.gs/1hNLO5D to join the world in running for those who can #39;t! Wings for Life World Run ambassador Brooke Thabit shares her personal story of ...

By: Red Bull

Continued here:
A surfer's optimism after tragic spinal cord injury - Brooke Thabit: A day in the life - Video

Recommendation and review posted by sam

Spinal Cord injury solvable since mid 90s for Nesu Mihaita
my tribute to romanian athlete Nesu Mihaita a short Discovery Channel clip about Spinal Cord injury - a solvable equation since mid 90s Copyright Disclaimer ...

By: marius molac

Originally posted here:
Spinal Cord injury solvable since mid 90s for Nesu Mihaita - Video

Recommendation and review posted by sam

Spinal cord injury sit ski Level C6 complete

By: takunori13

Link:
Spinal cord injury sit ski Level C6 complete - Video

Recommendation and review posted by sam

Vascular Integrity Test 07 March 2014
Vascular Integrity Test of pig heart bioscaffold using viscus fluorescent dye. Test was a success despite the aorta plug popping out at the end of the video.

By: Riddle Institute for Regenerative Medicine

See the original post:
Vascular Integrity Test 07 March 2014 - Video

Recommendation and review posted by sam

Knee Replacement vs. Stem Cell Therapy - Regenexx
Hundreds of thousands undergo knee replacement each year, but the outcomes are often not what people expect. The Regenexx-SD same day stem cell procedure off...

By: Regenexx

Read the original:
Knee Replacement vs. Stem Cell Therapy - Regenexx - Video

Recommendation and review posted by simmons

Stem cell transplant was viable and effective in halting or reversing degenerative disc disease of the spine, a meta-analysis of animal studies showed, in a development expected to open up research in humans. Recent developments in stem cell research have made it possible to assess its effect on intervertebral disc (IVD) height, Mayo Clinic researchers reported in a scientific poster today at the 30th Annual Meeting of the American Academy of Pain Medicine.

"This landmark study draws the conclusion in pre-clinical animal studies that stem cell therapy for disc degenerative disease might be a potentially effective treatment for the very common condition that affects people's quality of life and productivity," said the senior author, Wenchun Qu, MD, PhD, of the Mayo Clinic in Rochester, Minn.

Dr. Qu said not only did disc height increase, but stem cell transplant also increased disc water content and improved appropriate gene expression. "These exciting developments place us in a position to prepare for translation of stem cell therapy for degenerative disc disease into clinical trials," he said.

The increase in disc height was due to restoration in the transplant group of the nucleus pulposus structure, which refers to the jelly-like substance in the disc, and an increased amount of water content, which is critical for the appropriate function of the disc as a cushion for the spinal column, the researchers concluded.

The researchers performed a literature search of MEDLINE, EMBASE and PsycINFO databases and also manually searched reference lists for original, randomized, controlled trials on animals that examined the association between IVD stem cell transplant and the change of disc height. Six studies met inclusion criteria. Differences between the studies necessitated the use of random-effects models to pool estimates of effect.

What they found was an over 23.6% increase in the disc height index in the transplant group compared with the placebo group (95% confidence interval [CI], 19.7-23.5; p<0.001). None of the 6 studies showed a decrease of the disc height index in the transplant group. Increases in the disc height index were statistically significant in all individual studies.

The authors commented that it is time to turn attention to the much-needed work of determining the safety, feasibility, efficacy of IVD stem cell transplant for humans.

"A hallmark of IVD degenerative disease is its poor self-repair capacity secondary to the loss of IVD cells. However, current available treatments fail to address the loss of cells and cellular functions. In fact, many invasive treatments further damage the disc, causing further degeneration in the diseased level or adjacent levels," said the lead study author Jason Dauffenbach, DO. "The goal of tissue engineering using stem cells is to restore the normal function and motion of the diseased human spine."

Story Source:

The above story is based on materials provided by American Academy of Pain Medicine (AAPM). Note: Materials may be edited for content and length.

Original post:
Stem cell transplant shows 'landmark' promise for treatment of degenerative disc disease

Recommendation and review posted by simmons

Contact Information

Available for logged-in reporters only

Newswise March 7, 2014, Phoenix, AZ -- Stem cell transplant was viable and effective in halting or reversing degenerative disc disease of the spine, a meta-analysis of animal studies showed, in a development expected to open up research in humans. Recent developments in stem cell research have made it possible to assess its effect on intervertebral disc (IVD) height, Mayo Clinic researchers reported in a scientific poster today at the 30th Annual Meeting of the American Academy of Pain Medicine.

This landmark study draws the conclusion in pre-clinical animal studies that stem cell therapy for disc degenerative disease might be a potentially effective treatment for the very common condition that affects peoples quality of life and productivity, said the senior author, Wenchun Qu, MD, PhD, of the Mayo Clinic in Rochester, Minn.

Dr. Qu said not only did disc height increase, but stem cell transplant also increased disc water content and improved appropriate gene expression. These exciting developments place us in a position to prepare for translation of stem cell therapy for degenerative disc disease into clinical trials, he said.

The increase in disc height was due to restoration in the transplant group of the nucleus pulposus structure, which refers to the jelly-like substance in the disc, and an increased amount of water content, which is critical for the appropriate function of the disc as a cushion for the spinal column, the researchers concluded.

The researchers performed a literature search of MEDLINE, EMBASE and PsycINFO databases and also manually searched reference lists for original, randomized, controlled trials on animals that examined the association between IVD stem cell transplant and the change of disc height. Six studies met inclusion criteria. Differences between the studies necessitated the use of random-effects models to pool estimates of effect.

What they found was an over 23.6% increase in the disc height index in the transplant group compared with the placebo group (95% confidence interval [CI], 19.7-23.5; p<0.001). None of the 6 studies showed a decrease of the disc height index in the transplant group. Increases in the disc height index were statistically significant in all individual studies.

The authors commented that it is time to turn attention to the much-needed work of determining the safety, feasibility, efficacy of IVD stem cell transplant for humans.

A hallmark of IVD degenerative disease is its poor self-repair capacity secondary to the loss of IVD cells. However, current available treatments fail to address the loss of cells and cellular functions. In fact, many invasive treatments further damage the disc, causing further degeneration in the diseased level or adjacent levels, said the lead study author Jason Dauffenbach, DO. The goal of tissue engineering using stem cells is to restore the normal function and motion of the diseased human spine.

More:
Stem Cell Transplant Shows "Landmark" Promise for Treatment of Degenerative Disc Disease: Mayo Clinic

Recommendation and review posted by Bethany Smith

New research suggests noted northeast Indiana author and naturalist Gene Stratton-Porter also spent a lot of time in Fort Wayne visiting family, shopping and attending events. (News-Sentinel archive photo)

FORT WAYNE, Ind. (AP) Many people think of Gene Stratton-Porter as an avid naturalist and talented author who spent much of her time in the outdoors. But a new review of official records and newspaper reports of the day provides a fuller and sometimes conflicting picture of one of Indianas most famous women.

Stratton-Porter, for example, spent a lot of time in Fort Wayne, often taking the train here to go shopping, visit family or attend social events and lectures, researcher Terri Gorney of Fort Wayne told The News-Sentinel.

While lamenting the draining of the Limberlost Swamp near Geneva, Gorney also found Stratton-Porter and her husband, Charles, had 30 or more oil wells on their 239-acre farm 3 miles west of town, which required draining the swamp to install the wells.

Its fun, because I never know where its going to lead me, Gorney, 53, said of her search for information.

The News-Sentinel recently wrote about Gorneys research on early conservationists in northeast Indiana, which she started in 2007.

She began researching Stratton-Porter in 2009 at the suggestion of Randy Lehman, site manager for the Limberlost State Historic Site, the Porters large log home in Geneva. Gorney had become active with the Friends of the Limberlost, a nonprofit group that supports the state historic site and efforts to restore wetlands once part of the Limberlost Swamp.

She didnt think she would find much new about Stratton-Porter. But when she really starting digging in 2011, she was surprised.

Im still finding things, she said.

Gorney reads day by day through newspapers of the late 1800s and early 1900s in Fort Wayne, Geneva and Decatur. She also sifts through official land and other records, as well as archives containing letters Stratton-Porter wrote to other people.

The rest is here:
Research traces Fort Wayne ties of naturalist, author Gene Stratton-Porter

Recommendation and review posted by Bethany Smith

Infomercial 3: Genetic Engineering
Mrs Marsha, 3rd period, infomercial #3.

By: boricuarocky247

See the article here:
Infomercial 3: Genetic Engineering - Video

Recommendation and review posted by Bethany Smith

It cost over $3 billion and took almost 13 years to sequence the human genome for the first time, a task that was only completed a little over ten years ago.

Instead of our current one-size-fits all treatment for most diseases, many envision a future in which we will be able to tailor medical treatment based on ones underlying genetic information, a medical model known as personalized, or precision, medicine.

To better understand what it will take to reach these aims, which will require further advances in many disciplines and have implications stretching far beyond the field of medicine, University President Lee Bollinger recently announced the creation of a task force on personalized medicine.

When there are major advances in our knowledge that can be translated in very important effects for the world, we want to make sure as the university we are doing everything we can to facilitate that, Bollinger said at last weeks University Senate plenary.

The task force, co-chaired by Provost John Coatsworth and Dean of the Faculties of Health Sciences and Medicine Lee Goldman, brings together almost 40 faculty members across the entire university. Unlike other institutions, including various cancer centers, that are also working in personalized medicine, this task force will use a University-wide approach, rather than just a medical one.

The opportunity is really here now

They have the foresight to realize that this is not just a medical center problem, that this really permeates every different aspect of what we do at Columbia, said Dr. Wendy Chung, director of the Clinical Genetics Program at the Columbia University Medical Center and member of the task force. Its going to be challenging, I think, to get people who speak different languages to come together and to realize what they can contribute but Ive never seen any other initiative where so many people have come together to try and make it work.

Though the task force has yet to meet, it plans to produce a report next fall that outlines what Columbia should do in this emerging field of medicine.

Its almost certainly one of those things that you cant just leave to chance to happen. You have to get organized, you have to get the infrastructure, you have to figure out the kinds of intellectual work that you need to do, Bollinger said.

Personalized medicine will ultimately be the result of a more comprehensive understanding of the genetic underpinnings of disease, but to get to that point, researchers need more data than is currently available.

Read the rest here:
New task force on personalized medicine takes interdisciplinary approach

Recommendation and review posted by Bethany Smith

London, UK (PRWEB) March 07, 2014

During the last 20 years, the ongoing genetic advances have considerably facilitated the emergence of personalized medicine sector as an important player in the overall healthcare universe. Human genome sequencing has propelled the pharmacogenetics sector. Furthermore, personalized medicine also takes into account pharmacogenomics studies, where protein and genetic interactions yield the potential drug targets. The key objective of personalized medicine is to offer individualized care that is more effective and specific to the potential patients. Targeted and personalized medicine R&D efforts are aimed at increasing the efficiency of the therapeutic area via genetic testing along with companion diagnostics. The introduction of novel personalized medicine will likely reduce the frequency of adverse drug reactions and thus have a significant influence on health economics. Diagnostic and developmental companies are predicted to take benefit from lower discovery and commercialization costs, as well as from more specific market sub-types awaited in the years ahead.

Nodality, Celera, 23andMe, Myriad, Amgen, Atossa Genetics and Affymetrix are among the leading participants in the worldwide market for personalized medicine and companion diagnostic tests.

New research report Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment elaborated by Kelly Scientific Publications is available at MarketPublishers.com.

Report Details:

Title: Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment Published: March, 2014 Pages: 224 Price:US$ 3,835.00 http://marketpublishers.com/report/life_sciences/healthcare/personalized-medicine-n-companion-diagnostic-market.html

A cutting-edge all-round report provides a full detailed coverage of the world personalized medicine and companion diagnostic market as well as tackles the most significant industry related issues. The study presents insights into the historical background of the industry and illustrates the current situation in the market; summarizes the key factors influencing the market growth, and also reviews the major existing personalized medicine and companion diagnostic products and technologies. It traces the most recent important industry developments, identifies and scrutinizes the most prominent market trends, covers the actual scenario in the main geographical markets, investigates the competitive landscape and includes the leading companies profiles. Additionally, the report discusses the markets growth opportunities and grants access to a complete set of projections of the future performance of the personalized medicine and companion diagnostic market through 2017.

Reasons to Buy:

More new research reports by the publisher can be found at Kelly Scientific Publications page.

See the rest here:
Personalized Medicine and Companion Diagnostic Market Discussed in New Report by Kelly Scientific Publications ...

Recommendation and review posted by Bethany Smith

It cost over $3 billion and took almost 13 years to sequence the human genome for the first time, a task that was only completed a little over ten years ago.

Instead of our current one-size-fits all treatment for most diseases, many envision a future in which we will be able to tailor medical treatment based on ones underlying genetic information, a medical model known as personalized, or precision, medicine.

To better understand what it will take to reach these aims, which will require further advances in many disciplines and have implications stretching far beyond the field of medicine, University President Lee Bollinger recently announced the creation of a task force on personalized medicine.

When there are major advances in our knowledge that can be translated in very important effects for the world, we want to make sure as the university we are doing everything we can to facilitate that, Bollinger said at last weeks University Senate plenary.

The task force, co-chaired by Provost John Coatsworth and Dean of the Faculties of Health Sciences and Medicine Lee Goldman, brings together almost 40 faculty members across the entire university. Unlike other institutions, including various cancer centers, that are also working in personalized medicine, this task force will use a University-wide approach, rather than just a medical one.

The opportunity is really here now

They have the foresight to realize that this is not just a medical center problem, that this really permeates every different aspect of what we do at Columbia, said Dr. Wendy Chung, director of the Clinical Genetics Program at the Columbia University Medical Center and member of the task force. Its going to be challenging, I think, to get people who speak different languages to come together and to realize what they can contribute but Ive never seen any other initiative where so many people have come together to try and make it work.

Though the task force has yet to meet, it plans to produce a report next fall that outlines what Columbia should do in this emerging field of medicine.

Its almost certainly one of those things that you cant just leave to chance to happen. You have to get organized, you have to get the infrastructure, you have to figure out the kinds of intellectual work that you need to do, Bollinger said.

Personalized medicine will ultimately be the result of a more comprehensive understanding of the genetic underpinnings of disease, but to get to that point, researchers need more data than is currently available.

Continued here:
Task force on precision medicine takes interdisciplinary approach

Recommendation and review posted by Bethany Smith

Advanced Genetics Mod Spotlight -1st Video!-
In this mod spotlight I look at the Advanced Genetics Mod! Enjoy! Please Like, Comment, Favorite, and Subscribe! Mod Link: http://www.minecraftforum.net/topi...

By: JacobmobGames

View original post here:
Advanced Genetics Mod Spotlight -1st Video!- - Video

Recommendation and review posted by Bethany Smith

Attack of the B-Team - Automating Advanced Genetics
Today we #39;re gonna build an Advanced Genetics laboratory and try our darnedest to weed out some of the tedium involved in getting scrapings, processing them, ...

By: jsit

See the rest here:
Attack of the B-Team - Automating Advanced Genetics - Video

Recommendation and review posted by Bethany Smith